Background. Most respiratory syncytial virus (RSV) vaccine candidates include fusion (F) protein in different conformations. Antigenic site II found in the different F conformations is the target of palivizumab, the only US Food and Drug Administration approved monoclonal antibody (mAb). Serum palivizumab-like antibody (PLA) is a potential serologic correlate of immunity. Our objective was to determine if different conformations of F protein in a palivizumab competitive antibody (PCA) assay affect the PLA concentrations.
Respiratory syncytial virus (RSV) was first identified as the agent that causes chimpanzee coryza in 1956 [1] , and was then isolated from children with pulmonary disease in Baltimore, USA [2] . RSV is now recognized as the most common cause of lower respiratory tract infections (LRTI) in young children worldwide, and it is an important cause of LRTI in elderly people. Annually, RSV causes more than 50 000 hospitalizations among children younger than 5 years old [3] , and among older adults it causes approximately 170 000 hospitalizations and 14 000 deaths in the USA alone [4] . Reinfection is common throughout life and severe disease may occur in persons with chronic respiratory disease, immunodeficiency, or cardiac disease [5] . In a 2013 retrospective study of 280 hematopoietic cell transplant (HCT) recipients with RSV infection, the 90-day mortality rate was 16% [6] .
RSV expresses 3 surface proteins: the attachment (G) protein, the fusion (F) protein, and the small hydrophobic (SH) protein.
The G protein plays a role in host cell attachment and immune evasion [7] , the F protein causes the virion membrane to fuse with a target cell membrane [8] , and the SH protein inhibits apoptosis [9, 10] and acts as a viroporin [11] . The G and F glycoproteins are the only known RSV proteins that induce neutralizing antibodies after natural infection. Most RSV vaccine candidates include the F protein because it is highly conserved compared to the G protein [12] [13] [14] . The F protein exists in different conformations in the life cycle of the virion. There is controversy as to whether the F protein is in a prefusion or prefusogenic form on the surface of infected cells [15] [16] [17] . Similarly, it is uncertain whether virus entry occurs at the apical surface of respiratory epithelial cells by viruscell fusion or by micropinocytosis followed by a later fusion event [18, 19] . Exactly when and where fusion occurs notwithstanding, it appears to require conformational change of the metastable prefusion F (pre-F) to a transitional prehairpin intermediate and eventually to a stable 6-helix bundle postfusion F (post-F) form [20] [21] [22] . Pre-F and post-F forms share roughly 50% of their surface area, including antigenic sites II and IV [23] . At least 4 additional antigenic sites (Ø, III, V, and VIII) are specific to pre-F [23, 24] . Antigenic site I is unique to the post-F conformation [22] .
Currently, an RSV vaccine has not been approved by the US Food and Drug Administration (FDA) despite over 60 years of research, a large medical need, and a growing market potential. The pipeline of vaccine candidates is large and many vaccine candidates contain or express F protein [25] in either the prefusogenic [26] , pre-F [27] , post-F, or a mixture of forms [28] . A humanized monoclonal antibody (mAb), palivizumab (Synagis; MedImmune), was approved in 1998 by the FDA for the prevention of severe RSV disease in high-risk infants. Palivizumab at concentrations ≥40 µg/mL is associated with significant reduction of RSV-related hospitalization in high-risk infants [29] [30] [31] . Palivizumab binds exclusively to antigenic site II of the F protein [32, 33] . Palivizumab competitive antibody (PCA) assays containing different conformations of the F protein have been developed to measure palivizumab-like antibodies (PLA) concentrations. To date, the impact of the F protein conformation on the PCA assay has not been reported. Because antigenic site II is present in the different conformations of the F protein, measuring PLA activity might serve as a good immune correlate of protection for RSV vaccines in the pre-or post-F form. In this study, we used a panel of pre-F and post-F-specific mAbs to probe 4 F preparations with each preparation demonstrating a unique mAb binding pattern consistent with pre-F, intermediate F, or post-F forms. Subsequently, 4 PCA assays were developed to examine PLA in acute and convalescent sera of HCT adults acutely infected with RSV subgroups A (RSV/A) or B (RSV/B). We hypothesized that the 4 PCA assays should give comparable results without meaningful differences because antigenic site II is well conserved among the virus isolates in RSV/A and RSV/B subgroups and is found on both the pre-F and post-F forms of the F protein.
METHODS

Study Subjects
HCT recipients with laboratory-confirmed RSV upper respiratory tract infection at enrollment and negative chest radiography findings were enrolled within 72 hours of RSV diagnosis and stratified by level of risk for progression to the lower respiratory tract, as previously described [34] . From January 2012 to April 2015, sera were collected from all patients at enrollment (acute) and 14-60 days after hospitalization (convalescent). Nasal wash samples were collected at enrollment, day 7 (±1), day 14 (±1), and between day 21 and day 28 (±1). Medical records were reviewed to collect demographic and clinical data. The institutional review board of the University of Texas MD Anderson Cancer Center and Baylor College of Medicine approved the study protocol and written informed consent was obtained from all the participants.
Sucrose Purified RSV/A/Bernett
Sucrose purified RSV/A/Bernett (spRSV/A/Bernett) was purified using established methods [35, 36] . On average, spRSV contained 5 to 10 × 10 7 plaque-forming units per mL.
Enzyme-Linked Immunosorbent Assays
The F protein on RSV-infected HEp-2 cells (cell based), spRSV, and from a commercial lot (Life Technologies Corporation, Carlsbad, CA) were probed by 6 mAbs to assess the conformation of the F protein. The mAbs used were palivizumab (site II) (MedImmune, LLC, Geithersburg, MD), motavizumab (site II), D25 (site Ø), 5C4 (site Ø), AM14 (site V), and 131-2A (site I) (Millipore, Billerica, MA). The pre-F mAbs were kindly provided by Dr. Barney Graham (National Institute of Allergy and Infectious Diseases, National Institutes of Health). Immulon 2HB 96-well plates (Thermo Scientific) were coated with 100 µL of either spRSV (total protein 7 µg/mL) for 4 or 18 hours (spRSV-4h or spRSV-18h) or commercial F protein (0.25 µg/ mL) for 18 hours in 0.05 M carbonate-bicarbonate coating buffer (pH 9.6) at 4°C. For the cell-based RSV, HEp-2 cell monolayers (20 × 10 4 cells /mL) were prepared on 96-well Falcon tissue culture plates (Pittston, Pennsylvania). Cells were inoculated with spRSV (multiplicity of infection [MOI] = 0.1) and incubated at 37°C with 5% CO 2 and 85% humidity for 2 days. The plates from all 4 enzyme-linked immunosorbent assays (ELISAs) were blocked for 1 hour with 5% milk (Carnation Instant Nonfat Dry Milk). The 6 mAbs at concentration of 1.25 µg/mL in 5% milk were added in duplicate followed by 5-fold serial dilutions. Plates were then incubated at 37°C for 1 hour and washed with Kirkegaard and Perry Laboratories (KPL) wash (SeraCare Life Sciences, Gaithersburg, MD). Horseradish peroxidase (HRP)-conjugated goat anti-human IgG or goat anti-mouse IgG (BioRad Laboratories, Inc. Richmond, CA) at a dilution of 1:2000 was added and incubated for 1 hour at 37°C. The plates were developed with 3,3',5,5'-tetramethylbenzidine (TMB) Microwell Peroxidase Substrate System (Kirkegaard and Perry Labs) and the reactions were stopped with 0.16 N sulfuric acid. The developed plates were read at 450 nm on a Fluo-Star Optima plate reader.
Palivizumab Competitive Antibody Assay
Four types of PCA assays (spRSV-4h, spRSV-18h, commercial F, and cell-based RSV) were used to measure PLA concentrations in sera. Palivizumab was biotinylated with a Pierce Antibody Biotinylation Kit (Pierce, Rockford, IL) following manufacturer's instructions. Antigen coating, plate washing, blocking, color development, and plate reading were as described for the ELISA. A standard curve of palivizumab (2-fold serial dilution from 12 500 ng/mL to 24.41 ng/mL) was generated on each plate. Next, 50 µL of 2-fold serial dilutions of test sera (1:5 to 1:2560) in duplicate were added to the coated plates, followed by 50 µL of 100 ng/mL biotinylated palivizumab, and 1 hour incubation. After washing, HRP-conjugated streptavidin (SeraCare Life Sciences, Gaithersburg, MD) was added for an additional hour. Wells containing biotinylated palivizumab without sera served as positive controls representing maximum binding. Wells containing 5% milk instead of sera and wells containing sera without biotinylated palivizumab served as negative controls. A 4-parameter logistic regression model was used to calculate the PLA concentrations (µg/mL) based on the dynamic range of the standard curve by interpolating the concentration of the standards that corresponds to the absorbance value at which the test sample resulted in 50% inhibition. The lower limit of detection (LLoD) was 20 µg/mL for the cell-based RSV PCA assay and 1 µg/mL for the other 3 PCA assays. Sera with concentration below the LLoD were assigned a value of 10 µg/mL and 0.5 µg/mL for the cell-based RSV and the other 3 PCA assays, respectively.
Reverse-Transcription Polymerase Chain Reaction
Viral RNA extraction and RSV/A and RSV/B detection in nasal wash samples by reverse-transcription real-time polymerase chain reaction (RT-qPCR) were performed as previously described [34] .
RSV-Specific Microneutralization Assay
Serum was analyzed for neutralizing antibodies (Nt Ab) against RSV/A/Tracy and RSV/B/18537 in HEp-2 cells using a qualified microneutralization assay, as previously described [37] [38] [39] . Any sample resulting in a titer <LLoD (2.5 log 2 ) was assigned a value of 2 log 2 .
Statistical Analysis
For demographic characteristics and clinical outcomes, continuous variables were compared using 2-sample t test or Wilcoxon rank-sum test. Categorical variables were compared using the Χ 2 test or Fisher's exact test. An analysis of variance (ANOVA) and a paired t test were performed to test for differences in the means of log transformed PLA concentration between and within PCA assays, respectively. A 2-sample t test was used to determine whether the mean log transformed PLA concentration differed significantly between RSV/A and RSV/ B-infected patients, as well as between virus shedding duration of <14 and ≥ 14 days. Statistical significance was indicated for P values <0.025. Pearson's correlation coefficients were calculated for PLA concentrations between PCA assays, and to the RSV/A and RSV/B Nt Ab titers. Statistical analyses were performed using Stata 14 (Stata Corp, College Station, Texas).
RESULTS
Conformations of RSV F Protein
A panel of mAbs including pre-F-specific, post-F-specific, as well as mAbs that bind to both pre-and post-F sites, were used to probe the conformation of F protein in cell-based RSV, spRSV-4h, spRSV-18h, and commercial F protein by ELISA. Results illustrated in Figure 1A showed that the F protein in the cell-based RSV assay was recognized by all mAbs with equal intensity, indicating that cell-based RSV contains both pre-F and post-F forms of the F protein. SpRSV-4h was also recognized by all mAbs but at lower intensity with pre-F-specific mAbs 5C4 (site Ø) and AM14 (site V) ( Figure 1B) . The spRSV-4h likely contains various forms of F, which were named early intermediate F protein. The spRSV-18h was recognized by palivizumab and motavizumab with similar intensity to spRSV-4h; however, the intensity of D25 binding to F protein decreased, and the binding was completely lost for 5C4 and AM14 ( Figure 1C ). The spRSV-18h appeared to be composed mostly of post-F, which was named late intermediate F protein. The commercial F protein was recognized only by palivizumab and motavizumab targeting site II and post-F-specific mAb 131-2A targeting site I ( Figure 1D) , consistent with the post-F form.
Demographic and Clinical Variables of HCT Recipients
Clinical characteristics at enrollment are summarized for all 40 HCT adults in Table 1 , stratified by duration of RSV shedding (<14 or ≥14 days) or by RSV infection subtype (RSV/A or RSV/B). Age, gender, race/ethnicity, absolute neutrophil counts, absolute lymphocyte counts, and median time from HCT to RSV infection were comparable between the groups when stratified by duration of RSV shedding or by RSV infection subtype. The only significant difference observed was recipients who shed RSV for ≥14 days were more likely to have received an allogenic cell transplant compared to recipients with a shorter duration of viral shedding (18/20 versus 11/20, P <.025).
Comparison of PLA Concentrations Using Different Conformations of RSV F Protein
A significant increase in PLA geometric mean concentration in the convalescent sera compared to the acute sera was measured by all 4 assays ( Table 2 and Supplementary Table 1 for median values). The PLA concentrations (Table 2) tended to be higher in the cell-based RSV PCA assay; however, the fold-increase was higher for the PCA assays dominated by the post-F form (commercial F: fold-increase 5.6 and spRSV-18h: 5.6) compared to PCA assays containing pre-F (spRSV-4h: fold-increase 4.6 and cell-based RSV: 3.5).
For all the acute and convalescent sera, a significant difference of PLA concentrations between the PCA assays was detected (P <.001) ( Table 2 ). The proportion of individuals with no detectable PLA (<LLoD) or a protective PLA concentration (≥40µg/ mL) was also analyzed to better define the groups. Significant differences for these parameters were observed between the PCA assays. Few individuals had a protective PLA concentration in their acute sera. However, this increased in the convalescent sera to ≥ 35%.
Despite differences, there was a significant correlation between the commercial F PCA and the other 3 PCA assays. The correlation coefficients ranged from 0.56 to 0.93 for acute sera and 0.82 to 0.97 for convalescence sera (all correlations with P <.025). The lowest correlation coefficients for both acute (r = 0.56) and convalescence sera (r = 0.82) occurred between the commercial F and the cell-based RSV PCA assays (Figure 2A ). The highest correlation coefficients for both acute (r = 0.93) and convalescence sera (r = 0.97) were between spRSV-18h and spRSV-4h PCA assays ( Figure 2B ).
Comparison of PLA Concentrations Between RSV/A and RSV/B Infected
HCT Patients
No significant differences were observed in PLA concentration or proportion of HCT adults with no PLA or with protective PLA concentration in either the acute or the convalescent sera between HCT recipients infected with RSV/A versus RSV/B by any of the 4 PCA assays (Table 3 ). An increase in PLA concentration and proportion of HCT adults with protective PLA concentration were detected in the convalescent sera of RSV/A and RSV/B-infected HCT recipients by all 4 PCA assays (Table 3 ). This observation is consistent with antigenic site II being well conserved among RSV isolates in the RSV/A and RSV/B subgroups.
Comparison of PLA Concentrations in HCT Recipients Who Shed RSV for
<14 and ≥ 14 Days
The results showed that PLA concentration or proportion of HCT adults with no PLA or with protective PLA concentration in the acute sera was not significantly different in those who shed virus for <14 days compared to those who shed for ≥14 days by all 4 PCA assays (Table 4) . However, a statistically significant increase in PLA concentration was measured in convalescent sera in HCT recipients who shed virus for <14 days compared to those who shed for ≥14 days by all 4 PCA assays (Table 4) . Also a significant increase in the proportion with protective PLA concentration was detected by all PCA assays, except for the cell-based PCA assay.
Correlation of PLA and Neutralizing Antibody
We observed a significant positive correlation between PLA concentration measured by the 4 PCA assays and Nt Ab titer measured by the microneutralization assay against RSV/A and RSV/B. Correlation coefficients ranged from 0.48 to 0.83 with P <.025. The spRSV-4h PCA assay ( Figure 3A , B) produced the highest correlation and the commercial F assay ( Figure 3C, D) gave the lowest correlation observed between PLA concentration and Nt Ab titer in RSV-infected HCT adults. 
DISCUSSION
To our knowledge, this is the first study to evaluate the impact of different conformations of the F protein on PLA concentration in RSV-infected individuals. The conformation of the F protein used in each of the 4 PCA assays was probed by a panel of mAbs that targeted pre-F and post-F antigenic sites on the F protein. The mAb binding patterns were consistent with a pre-F for the cellbased RSV PCA assay, post-F for the commercial F PCA assay, and various forms of F, which were named early (spRSV-4h) or late (spRSV-18h) intermediate F forms. These 4 different F protein preparations were used to generate PCA assays that were probed with acute and convalescent sera from RSV-infected HCT adults. The 4 PCA assays were able to detect a significant increase in PLA concentration in the convalescent sera compared to the acute sera, and measure comparable rises in PLA concentration whether the HCT recipients were infected with RSV/A or RSV/B. A significant increase in PLA concentration in the convalescent sera was associated with a decrease in RSV shedding. In addition, high correlations were observed between the PCA assays, and between PLA concentration to RSV/A and RSV/B Nt Ab titer. Overall, the cell-based RSV, spRSV-4h, spRSV-18h, and commercial F PCA assays behaved similarly despite having the F protein in different conformations, and the cell-based RSV PCA assay giving quantitatively higher results. Our findings support the hypothesis that pre-F and post-Fbased PCA assays will generate comparable overall results, although there are quantitative differences in PLA concentrations. The PCA assay performance with pre-F, post-F, and the various forms of F (spRSV-4h and spRSV-18h) were consistent with the existing literature for the F protein. Crystal structures of the pre-F Table 1 Abbreviations: LLoD, lower limit of detection; SpRSV-4h, sucrose purified RSV 4 hours' coating; SpRSV-18h, sucrose purified RSV 18 hours' coating. b Percent (n).
. Demographic and Clinical Characteristics of Respiratory Syncytial Virus (RSV)-Infected Hematopoietic Cell Transplant (HCT) Recipients, Stratified by Duration of RSV Shedding (< 14 vs ≥ 14 days) and by RSV Type (RSV/A vs RSV/B)
c Two-sample t test for difference in means of log transformed PLA concentration or Fisher's exact test for difference in proportions between RSV/A and RSV/B.
Abbreviations: LLoD, lower limit of detection; N/A, not applicable; SpRSV-4h, sucrose purified RSV 4 hours' coating; SpRSV-18h, sucrose purified RSV 18 hours' coating. and post-F forms of F protein revealed the presence of antigenic site II on the surface of these two F forms [40] . Antigenic site II is well conserved among the RSV isolates in the different genotypes of RSV/A and RSV/B subgroups [41] . Both palivizumab and motavizumab are mAbs that target antigenic site II, and have been shown to be effective in preventing severe RSV infection in high-risk infants [42, 43] . MAbs are used to characterize the F protein conformation based on their binding pattern [44] . In our study, palivizumab and motavizumab were the only mAbs that bound the 4 different matrices. The matrix for the cell-based assay was RSV-infected HEp-2 cells. This matrix is expected to contain mostly pre-F, which was supported by the mAb binding pattern ( Figure 1A ). The matrix for the spRSV PCA assays was infectious spRSV that was coated on plates for 4 or 18 hours. It is possible that the coating buffer caused conformational changes to the F protein with longer coating time, leading to greater amounts of the post-F form. These changes were supported by the mAb binding patterns going from an early intermediate to a late intermediate F form (Figure 1B, C) . The commercial F was expected to be in a post-F form only and this was supported by the mAb binding pattern observed ( Figure 1D ).
The cell-based RSV PCA and spRSV PCA assays but not the commercial F PCA assay are different from F protein PCA assays previously reported [28, 45] . PCA assays have been developed by biotechnology companies interested in measuring PLA concentration induced by RSV F vaccine or for measuring PLA concentration in infants receiving palivizumab immunoprophylaxis [28, 45, 46] . The matrix used in these PCA assays is either prefusogenic F or post-F. Similar to our data, most adults have low levels of PLA concentration at baseline and prior to an RSV infection, and PLA concentration in adults rises significantly after boosting with an RSV F vaccine [28] or, as in our case, after an RSV infection. The magnitude of the PLA response induced by an RSV F vaccine appeared comparable to what we observed following RSV/A or RSV/B infection.
PCA assay might be considered to be a functional assay because it measures antibodies that compete against palivizumab for antigenic site II on the F protein. Palivizumab and motavizumab have been shown to be efficacious in phase III clinical trials in high-risk infants. In the IMpact trial, serum concentration of palivizumab above 30 to 40 µg/mL was associated with an efficacy of 55% in preventing RSV hospitalization for all high-risk infants and about 80% in a cohort of preterm infants 32-35 weeks gestational age [47] . In our study, we observed that a higher proportion of subjects with ≥ 40 µg/mL of PLA concentration in their convalescent sera cleared their RSV infection more quickly. We also detected a high correlation between PLA concentration and RSV-specific Nt Ab titer, consistent with the attribute of the PCA assay measuring functional antibody activity.
Our study has some limitations. The small number of RSVinfected HCT adults (n = 40) is not representative of adults in the general population. Higher rises in PLA concentration after an RSV infection is likely to occur in healthy adults compared to the HCT adults. The F conformations were determined by a panel of mAbs [44] instead of X-ray crystallographic data [12] . Other than commercial F, the quantity (µg/mL) or percentage of pre-F and post-F in the cell-based RSV, sp-RSV-4h, and spRSV-18h could not be determined. The cell-based PCA assay is a mixture of pre-and post-F forms and thus not truly representative of a pure pre-F PCA assay. However, the panel of mAb informed us of the major F forms detected in the different preparations used in the PCA assays.
In summary, post-F, pre-F, and various conformations of F protein used in the PCA assay measured comparable rises in PLA concentration after RSV infection in HCT recipients. Infections caused by RSV/A and RSV/B produced comparable increases in PLA concentration consistent with antigenic site II being conserved among the RSV/A and RSV/B. Increase in PLA concentration correlated with increase in RSV-specific Nt Ab titers and reduced RSV shedding. Thus, the conformation of the F protein does not appear to have a measurable impact on the PCA assay, and PLA concentration has the potential to serve as an immune correlate of protection against RSV infection.
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